Pharmacological Activation of HMN for OSA Aim 2

Description

Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. OSA patients show a marked reduction in upper airway (UA) dilator muscle activity at sleep onset and this phenomenon leads to increased collapsibility of UA compared to normal subjects. In this protocol the investigators will test the effect of LTM1201AZ, LTM1201AT, LTM1201AD, LTM1201AG administered before sleep on OSA phenotype traits and OSA severity during sleep.

Conditions

Obstructive Sleep Apnea

Talk to us

Study Overview

On this page

Study Details

Study overview

Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. OSA patients show a marked reduction in upper airway (UA) dilator muscle activity at sleep onset and this phenomenon leads to increased collapsibility of UA compared to normal subjects. In this protocol the investigators will test the effect of LTM1201AZ, LTM1201AT, LTM1201AD, LTM1201AG administered before sleep on OSA phenotype traits and OSA severity during sleep.

Pharmacological Activation of Hypoglossal Motor Nucleus for Obstructive Sleep Apnea Aim 2

Pharmacological Activation of HMN for OSA Aim 2

Condition
Obstructive Sleep Apnea
Intervention / Treatment

-

Contacts and Locations

Boston

Brigham and Women's Hospital, Boston, Massachusetts, United States, 02115

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * AHI \> 10 events/h during NREM supine sleep
  • * Any medical condition other than well controlled hypertension and mild diabetes.
  • * Any medication known to influence breathing, sleep/arousal, or muscle physiology.
  • * Claustrophobia.
  • * Inability to sleep supine.
  • * Allergy to any of the medications tested in the protocol.
  • * History of kidney stones, hypercalcemia, primary hyperparathyroidism, sarcoidosis, hypervitaminosis D.
  • * Individuals with underlying cardiac disease, such as arrhythmias.
  • * Individuals taking psychiatric medications, such as an MAO-I, SSRI or SNRI, or any of the studied medications for medical care.
  • * For women: Pregnancy.
  • * Pulmonary hypertension
  • * Severe OSA with a mean SaO2 lower than 88%

Ages Eligible for Study

18 Years to 70 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Brigham and Women's Hospital,

Study Record Dates

2022-12-31